RT Book, Section
A1 Thompson, Philip A.
A1 Rezvani, Katayoun
A1 Kebriaei, Partow
A2 Kantarjian, Hagop M.
A2 Wolff, Robert A.
SR Print(0)
ID 1126741412
T1 Cellular Therapy in Allogeneic Hematopoietic Cell Transplantation
T2 The MD Anderson Manual of Medical Oncology, 3e
YR 2016
FD 2016
PB McGraw-Hill Medical
PP New York, NY
SN 9780071847940
LK accessmedicine.mhmedical.com/content.aspx?aid=1126741412
RD 2024/04/20
AB The  efficacy  of  allogeneic  hematopoietic  cell  transplantation  (HCT)  in  hematologic  malignancies  can  in  large  part  be  attributed  to  a  graft-versus-tumor  (GVT)  effect,  by  which  the  donor  immune  system  achieves  immunologic  control  of  the  tumor.  As  such,  it  is  the  prototype  of  cellular  therapy.  The  human  leukocyte  antigen  (HLA)  system  is  fundamental  to  transplant  biology.  The  HLAs  are  highly  polymorphic  proteins  that  have  a  key  role  in  antigen  presentation  and  immunoregulation.  Class  I  HLAs  are  expressed  on  the  surfaces  of  all  nucleated  cells;  class  II  are  expressed  on  specialized  antigen-presenting  cells  (APCs),  such  as  macrophages,  dendritic  cells,  and  B  cells.